Clinical Trial

A Study of LM-24C5 For Advanced Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated September 9, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
To assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D)/optimal biologic dose (OBD) and/or Maximum Tolerated Dose (MTD) for LM-24C5 in subjects with advanced solid tumors.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-12-17; most recent amendment 2025-09-07.
Status change: Not Yet Recruiting → Recruiting 2024-01-02
Trial Details
NCT Number NCT06187402
Lead Sponsor LaNova Medicines Limited
Conditions Advanced Solid Tumor
Enrollment 49 participants
Start Date 2023-12-20
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-09-09